2026 Market SizeUSD 17.2 BnBase year
2027 EstimateUSD 17.8 BnEstimated year
2036 ForecastUSD 23.7 BnForecast value
CAGR3.2%2027–2036
Largest RegionNorth America2026
Infectious Disease Diagnostics Testing Market Overview
The global infectious disease diagnostics testing market is estimated at USD 17.2 billion in 2026, increasing to USD 17.8 billion in 2027 and projected to reach USD 23.7 billion by 2036, reflecting a 3.2% CAGR for 2027–2036.
23Respiratory pathogen targets supported by BIOFIRE RP2.1plusbioM - rieux
13Pathogens in Cepheid Xpert Respiratory PanelCepheid
20 minRoche cobas liat STI molecular testing turnaroundRoche
2025WHO consolidated TB diagnosis guidance updatedWHO
The market includes clinical assays, reagents, diagnostic kits and dedicated testing systems used to detect infectious pathogens in patient specimens. It encompasses molecular nucleic acid amplification, immunoassay and antigen-based testing, microbiology and selected rapid near-patient tests. Revenue attributable to general-purpose instruments is counted only where linked to infectious disease diagnostics; pharmaceutical therapies, broad laboratory infrastructure and epidemiological surveillance software are outside the defined market boundary.
In August 2025, the World Health Organization updated its tuberculosis diagnosis handbook, bringing together recommendations for TB disease, infection and drug-resistance testing. The guidance addresses automated nucleic acid amplification, targeted sequencing and diagnostic algorithms for patients with and without HIV. These recommendations support demand for accurate, decentralized and laboratory-based infectious disease detection while highlighting the practical challenges of sample handling, affordability and implementation.
In August 2025, Roche announced FDA clearance for its cobas Respiratory 4-flex assay, which detects SARS-CoV-2, influenza A, influenza B and RSV using the cobas 5800, 6800 and 8800 systems. In January 2025, Roche also announced clearance and a CLIA waiver for cobas liat STI assays, with results in 20 minutes. These developments demonstrate the simultaneous commercial emphasis on high-throughput laboratories and rapid near-patient testing.
The CDC distinguishes rapid antigen tests from nucleic acid amplification methods, noting that antigen assays generally offer faster results but can miss infections that molecular testing detects. Multiplex assays can help clinicians differentiate co-circulating respiratory pathogens and inform treatment and infection-control decisions. Hospitals, diagnostic reference laboratories and community care sites therefore procure different assay configurations depending on patient acuity, throughput, cost, available personnel and local testing recommendations.
Source: WHO TB diagnosis guidance; Roche respiratory clearance; CDC respiratory testing; Roche STI point-of-care testing.
Key Takeaways: Infectious Disease Diagnostics Testing Market
- Base-year market size: Global infectious disease diagnostic testing revenue is modeled at USD 17.2 billion in 2026.
- Forecast trajectory: The market is estimated at USD 17.8 billion in 2027 and forecast at USD 23.7 billion in 2036, a 3.2% CAGR.
- Leading type: Molecular diagnostics represented an estimated ~44% of 2026 revenue, supported by laboratory PCR and rapid nucleic acid amplification.
- Leading application: Respiratory infection testing represented an estimated ~31% of 2026 revenue, spanning influenza, SARS-CoV-2, RSV and broader syndromic panels.
- Largest region: North America represented an estimated ~38% of 2026 revenue, reflecting established laboratory and point-of-care testing infrastructure.
- Demand drivers: Multiplex assay menus, tuberculosis screening, STI test-to-treat workflows and pathogen surveillance underpin ongoing diagnostic utilization.
- Competitive landscape: Abbott, Roche, bioM - rieux, BD, Cepheid and Hologic market distinct molecular testing systems and assay menus.
- Report coverage: The analysis provides 2027–2036 forecasts across four segmentation dimensions and five geographic regions.
Report Scope & Market Segmentation
The study measures commercial revenue from infectious disease diagnostic test products and pathogen-specific assay platforms, differentiating test technologies, clinical indications, care settings and specimen workflows.
| Report Attribute | Coverage |
|---|
| Base Year | 2026 |
| Estimated Year | 2027 |
| Forecast Period | 2027–2036 |
| Market Measurement | Revenue, USD million/billion |
| By Technology | Molecular Diagnostics; Immunoassays and Antigen Tests; Microbiology and Culture; Other Methods |
| By Application | Respiratory Infections; Sexually Transmitted Infections; Tuberculosis and Other Mycobacterial Diseases; Gastrointestinal Infections; Bloodborne and Other Infections |
| By End User | Hospitals; Independent Diagnostic Laboratories; Clinics and Point-of-Care Settings; Other Users |
| By Test Setting | Central Laboratory; Near-Patient / Point of Care; Home and Self-Testing |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; China; Japan; India; Brazil; Mexico; South Africa |
| Key Market Players | Abbott Laboratories; Roche Diagnostics; bioM - rieux SA; Becton, Dickinson and Company; Cepheid (Danaher); Hologic Inc.; Certest Biotec |
Market Definition & Revenue Boundaries
The commercial boundary includes single-pathogen and syndromic molecular panels, immunoassay and antigen-based test kits, microbiological diagnostic reagents, and dedicated testing instruments when attributable to infectious disease use. It excludes general-purpose laboratory equipment without an attributable infectious disease revenue component, pharmaceuticals, vaccines, infection-control consumables and unrelated genetic screening services.
By technology, molecular tests detect pathogen nucleic acids, while antigen and immunoassay formats detect proteins or host responses. Application categories are mutually exclusive according to the primary clinical indication. End-user and setting dimensions classify the same underlying market independently rather than representing additive revenue pools. The 2026 baseline and 2027–2036 forecast are publisher-endpoint-normalized projections based on supplied 2024 and 2032 revenue endpoints.
Infectious Disease Diagnostics Testing Market Dynamics
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2027–2029 | 2030–2032 | 2033–2036 |
|---|
| Multiplex assay menus improving clinical decision support | High | +1.50% | High | High | Medium |
| Expansion of rapid molecular testing at care sites | High | +1.30% | High | Medium | Medium |
| TB and drug resistance testing requirements | Medium | +1.10% | Medium | High | High |
| Installed laboratory platform menu expansion | Medium | +0.90% | High | Medium | Medium |
| Others (infection surveillance and laboratory upgrades) | Low | +0.50% | Medium | Medium | Low |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2027–2029 | 2030–2032 | 2033–2036 |
|---|
| Cost and reimbursement pressure on diagnostic testing | High | -0.90% | High | High | High |
| Infrastructure and workforce constraints | Medium | -0.70% | High | Medium | Medium |
| Others (regulatory validation and procurement delays) | Medium | -0.50% | Medium | Medium | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 3.2% CAGR for 2027–2036; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
Multiplex molecular testing expands clinical diagnostic utility
Roche received FDA clearance for cobas Respiratory 4-flex in August 2025, allowing four respiratory viruses to be differentiated on its high-throughput cobas systems. Cepheid also markets a 13-pathogen respiratory panel for GeneXpert, while bioM - rieux offers BIOFIRE respiratory panels covering up to 23 targets. The broader assay menus can consolidate clinical workups when patients have overlapping respiratory symptoms. Laboratory adoption depends on specimen volume, instrument compatibility and whether the additional targets change clinical management. Demand therefore favors validated panels that improve actionable diagnosis rather than indiscriminately adding every possible pathogen.
Tuberculosis and antimicrobial resistance require timely testing
WHO updated its consolidated tuberculosis diagnosis guidance in 2025 to address disease, infection and drug-resistance testing together. The recommendations include low-complexity automated nucleic acid amplification, targeted next-generation sequencing and testing algorithms for vulnerable populations. Such guidance creates opportunities for molecular testing in high-burden countries, but implementation requires specimen transport, quality assurance, trained staff and affordable consumables. Procurement decisions can favor systems that combine pathogen detection with actionable resistance information. Budget constraints and gaps in rural laboratory infrastructure remain material barriers to broad deployment.
Point-of-care access shortens the diagnostic-to-treatment interval
Roche announced FDA clearance and CLIA waiver for cobas liat STI molecular assays in January 2025, with a test time of 20 minutes. Abbott markets the ID NOW platform for rapid molecular detection of infectious pathogens. These technologies support same-visit decision-making in urgent care, community clinics and other decentralized settings where patients might otherwise be lost to follow-up. However, throughput and test-menu breadth differ from central laboratories, and per-test economics can be sensitive to staffing, quality control and reimbursement. Point-of-care adoption consequently complements rather than fully displaces centralized diagnostic testing.
Sensitivity, interpretation and stewardship constrain test selection
CDC guidance explains that antigen tests typically deliver rapid results but are generally less sensitive than nucleic acid amplification tests. In patients with serious disease or high clinical suspicion, a negative antigen result may require follow-up molecular testing. The clinical value of broad multiplex panels also depends on interpretation: detection of a pathogen does not automatically establish causation, and antibiotic selection requires clinical judgment. Laboratories must balance accuracy, turnaround time and cost against clinical utility. These factors limit indiscriminate expansion of test volumes even as assay technologies become faster and more comprehensive.
Regulatory and workflow requirements influence commercialization
Hologic announced FDA clearance and European IVDR CE marking for Panther Fusion gastrointestinal bacterial assays in October 2025. BD reported IVDR certification of VIASURE respiratory and STI assays for its BD MAX system in December 2025. These announcements illustrate how regional regulatory pathways and instrument compatibility shape market access. Laboratories also evaluate validation, quality controls, sample preparation and information-system integration before changing established workflows. Manufacturers with installed instrument bases may benefit from menu expansion, while new entrants face procurement cycles and regulatory costs that can slow adoption.
Sources: WHO tuberculosis diagnosis guidance (2025); CDC respiratory testing guidance (2025); Roche (2025); Hologic (2025); BD (2025).
Market Trends & Growth Opportunities
Syndromic panels combine respiratory and gastrointestinal pathogen targets
Manufacturers are extending multiplex molecular assay menus to address overlapping clinical syndromes. bioM - rieux lists respiratory, gastrointestinal and blood-culture identification panels on its BIOFIRE FILMARRAY TORCH system. Cepheid markets a respiratory panel identifying 13 viral and bacterial targets, while BD has expanded its BD MAX menu through partner-developed assays. The value proposition is a more focused diagnostic workup with fewer sequential orders, particularly for patients whose symptoms do not identify a single pathogen. Laboratories nevertheless must assess the appropriateness of panel breadth and the incremental cost per actionable result.
Molecular STI diagnostics move into decentralized clinical settings
Roche reported U.S. clearance and CLIA waiver for cobas liat CT/NG and CT/NG/MG assays in January 2025. The company describes molecular results in 20 minutes, supporting same-visit decisions for patients with suspected sexually transmitted infections. Near-patient testing can be particularly valuable where return visits are uncertain, but operators must still follow specimen and quality-control requirements. Manufacturers are positioning compact analyzers as extensions of established laboratory testing rather than replacements for all centralized workflows. Clinical adoption will depend on reimbursement, local STI burden and treatment pathways.
Public-health guidance strengthens targeted TB diagnostic algorithms
WHO consolidated its 2025 recommendations for tuberculosis infection, active disease and drug resistance, including automated molecular testing and targeted sequencing. The shift emphasizes matching test technology to patient characteristics and the need for resistance information. Implementation in high-burden settings depends on supply chains, specimen handling, training and access to confirmatory testing. Procurement programs may favor robust assays with predictable turnaround and transparent quality assurance. This trend can support demand for decentralized molecular platforms while creating pressure for lower total testing costs.
Laboratory systems compete on throughput and assay flexibility
Roche cobas 5800, 6800 and 8800 systems support its Respiratory 4-flex test, whereas BD MAX combines extraction and real-time PCR in an automated workflow. Hologic Panther Fusion offers gastrointestinal and respiratory assay menus, and bioM - rieux emphasizes syndromic panels. Buyers evaluate instrument utilization, reagent supply, turnaround time and the cost of training when choosing a platform. An existing installed base can reduce the cost of adopting an additional assay, but it can also create switching barriers. Competition therefore increasingly concerns workflow integration as well as individual test performance.
At-home and point-of-care formats require differentiated evidence
CDC respiratory testing guidance distinguishes at-home antigen and molecular testing from laboratory-based assays, with important differences in sensitivity and interpretation. Home testing may improve convenience, but negative results can require clinical follow-up when symptoms and risk remain high. At the same time, rapid molecular platforms such as Abbott ID NOW provide near-patient detection under appropriate professional workflows. Manufacturers must validate specimen types and intended-use populations for each product. This segmentation favors complementary test formats, rather than assuming all infectious disease testing will migrate to consumer self-testing.
Infectious Disease Diagnostics Testing Market Segmentation by Technology
Report SegmentationBy Technology
Technology demand spans molecular nucleic acid testing, immunoassays, culture-based methods and other techniques. Assay selection depends on clinical indication, turnaround time, sample type, laboratory capacity and the importance of detecting resistance or differentiating pathogens.
Leading TechnologyMolecular Diagnostics
Molecular diagnostics represented an estimated ~44% of 2026 revenue. PCR and other nucleic acid amplification formats serve high-throughput laboratories and near-patient sites. Roche, Cepheid, Hologic and BD offer automated platforms with different menus and throughput characteristics. Molecular testing is particularly useful where sensitivity and pathogen differentiation influence clinical decisions.
Rapid TestingImmunoassays and Antigen Tests
Antigen and immunoassay formats serve clinical settings requiring accessible testing and fast initial decisions. CDC guidance cautions that antigen tests can be less sensitive than nucleic acid amplification, so some negative results require clinical follow-up. CDC identifies antigen testing as a rapid option for respiratory virus detection in appropriate clinical and home settings.
Conventional TestingMicrobiology and Culture
Culture-based testing remains important when organism recovery and susceptibility workups are required. Its workflow is often slower than direct molecular detection, but laboratories retain culture capacity for clinical and antimicrobial stewardship reasons.
Technology mix depends on the clinical question and laboratory infrastructure. Molecular methods gain menu breadth, while immunoassays and culture remain complementary. Procurement teams compare total costs, quality-control demands, instrument utilization and local disease prevalence before selecting assays. Clinical evidence also matters because a faster result has value only when it changes care decisions. Emerging platforms must demonstrate dependable performance across the intended specimen types and patient populations.
Infectious Disease Diagnostics Testing Market Segmentation by Application
Report SegmentationBy Application
Applications include respiratory infections, sexually transmitted infections, tuberculosis, gastrointestinal infections and bloodborne or other infectious conditions. Testing volumes reflect local disease burden and clinical guidelines rather than a single global diagnostic pathway.
Leading ApplicationRespiratory Infections
Respiratory infections represented an estimated ~31% of 2026 revenue. Seasonal influenza, RSV, SARS-CoV-2 and other respiratory pathogens support multiplex testing demand. Roche received clearance for a four-target respiratory assay in August 2025, while Cepheid and bioM - rieux offer broader panels.
Decentralized TestingSexually Transmitted Infections
STI testing is shifting toward rapid molecular detection in community clinics and urgent care. Roche announced CLIA-waived cobas liat assays for CT, NG and MG targets in January 2025, supporting treatment decisions within a single visit.
Public-Health PriorityTuberculosis and Other Mycobacterial Diseases
WHO 2025 guidance addresses tuberculosis infection, disease and drug resistance. Molecular screening and sequencing can support earlier clinical decisions, but access depends on procurement, transport and laboratory quality systems.
Syndromic OpportunityGastrointestinal Infections
Hologic obtained FDA clearance for Panther Fusion gastrointestinal bacterial assays in October 2025. Gastrointestinal panels can detect multiple pathogens from a specimen, helping reduce sequential testing where clinical indications support their use.
Broader TestingBloodborne and Other Infections
HIV and hepatitis viral-load monitoring, bloodstream infection identification and healthcare-associated infection testing create demand beyond respiratory and gastrointestinal indications. Assay adoption depends on national screening recommendations and care infrastructure.
The application portfolio remains diversified across acute, chronic and public-health testing requirements.
Infectious Disease Diagnostics Testing Market Segmentation by End User
Report SegmentationBy End User
Hospitals, independent laboratories, community clinics and other providers use different testing systems. Patient acuity, assay throughput and the availability of qualified personnel influence the distribution of testing expenditure.
Hospital DemandHospitals
Hospitals combine emergency respiratory testing, gastrointestinal pathogen diagnostics and inpatient microbiology. Automated molecular platforms support workflows where results can influence isolation decisions and treatment, although procurement depends on instrument capacity and reimbursement.
Reference Laboratory DemandIndependent Diagnostic Laboratories
Independent laboratories consolidate samples from multiple providers and use high-throughput analyzers for broad test menus. Reference laboratories assess instrument uptime and specimen transport to support reliable turnaround for samples received from multiple providers.
Decentralized CareClinics and Point-of-Care Settings
Urgent care and community clinics can use rapid molecular or antigen testing for same-visit clinical decisions. Compact platforms may reduce delays but often trade throughput for proximity to the patient.
Other UsersOther Users
Public-health laboratories, outreach programs and specialized screening providers account for additional demand, especially for tuberculosis and other infections requiring surveillance or targeted screening.
Laboratory and point-of-care channels coexist, with clinical urgency and total cost of testing shaping deployment. Hospital laboratories often prioritize breadth and continuous operation, while community clinics place greater emphasis on training requirements and fast results. Public-health programs must also consider reliable consumable supply and regional access. The same manufacturer may serve multiple end-user categories with different instrument and assay combinations.
Infectious Disease Diagnostics Testing Market Segmentation by Test Setting
Report SegmentationBy Test Setting
Test setting separates central laboratories, professional near-patient testing and home self-testing. The same pathogen may be detected by multiple technologies, but intended use and interpretation differ materially across settings.
Centralized WorkflowsCentral Laboratory
Central laboratories operate automated molecular and microbiology workflows with quality controls, specimen batching and broad assay menus. Installed systems from Roche, Hologic, BD and other manufacturers support high-throughput use.
Rapid Professional TestingNear-Patient / Point of Care
Near-patient platforms support clinical decisions at urgent care and community sites. Roche cobas liat and Abbott ID NOW illustrate compact molecular systems, with menu, throughput and operator requirements varying by platform.
Convenient AccessHome and Self-Testing
At-home respiratory tests improve convenience, particularly for common viral infections. CDC guidance distinguishes antigen and molecular self-tests and cautions that a negative antigen result may not rule out infection. Complex microbiological investigations and high-throughput molecular panels continue to require professional laboratory infrastructure.
Regulatory authorization and specimen instructions determine which settings are appropriate for each test. Centralized molecular systems can support complex pathogen panels and large specimen volumes, whereas home tests typically focus on simpler workflows. Clinicians may order confirmatory tests when symptoms or risk conflict with a negative initial result. Purchasers should evaluate clinical sensitivity, turnaround time, quality systems and the costs of specimen handling before substituting one setting for another. Clinical settings differ in throughput, staffing and specimen handling requirements.
Infectious Disease Diagnostics Testing Market Regional Analysis
Regional demand reflects infection burden, reimbursement, laboratory capacity, procurement budgets and the adoption of rapid molecular testing. North America is modeled as the largest market by revenue, while Asia-Pacific presents substantial long-term diagnostic access opportunities.
North America
Largest market - ~38% of global revenue in 2026North America represented an estimated ~38% of global revenue in 2026. The United States has extensive hospital, reference laboratory and urgent-care testing infrastructure, supporting both automated molecular systems and decentralized diagnostics. CDC recommendations for respiratory testing and influenza molecular assays inform clinical decisions, while manufacturers continue to expand FDA-cleared test menus. Roche announced clearance of cobas Respiratory 4-flex in August 2025 and STI molecular assays in January 2025. Hologic and BD have also expanded their infectious disease offerings. Spending is shaped by reimbursement and instrument utilization rather than infection burden alone. The region benefits from broad access to sophisticated platforms, although pricing and utilization management can moderate revenue growth. United States and Canadian testing services are shaped by established referral networks, reimbursement and FDA-cleared assay menus. Public-health guidance can influence when clinicians request multiplex tests and when confirmation is warranted. Installed analyzer bases create practical advantages for compatible new assay launches.
Priority country signals
United States
Selected market signalCDC guidance distinguishes antigen and molecular respiratory tests and explains when multiplex testing can guide clinical management. FDA-cleared assays from Roche and Hologic illustrate continuing expansion of U.S. testing menus. U.S. procurement decisions also reflect FDA-authorized indications and CDC testing recommendations. For American providers, test ordering also depends on whether a result will change antiviral treatment or infection-control decisions. Laboratories compare multiplex molecular assays with lower-cost rapid antigen workflows and follow applicable FDA authorizations.
Source: CDC.
Canada
Selected market signalCanadian laboratories use a mix of centralized and near-patient diagnostics, with adoption influenced by provincial procurement and clinical guidelines. Demand is expected to favor tests that fit existing instrument infrastructure and address respiratory, gastrointestinal and bloodborne infections. Canadian providers must coordinate laboratory testing capacity with geographically dispersed patient populations. Rural specimen transport and provincial procurement can shape whether rapid near-patient testing is cost-effective.
Source: WHO.
Europe
Mature laboratory market - IVDR shapes assay accessEurope has established diagnostic laboratory networks and an active regulatory transition under the In Vitro Diagnostic Regulation. BD announced IVDR-certified VIASURE respiratory and STI assays for its BD MAX system in December 2025, demonstrating how compliance and menu expansion influence commercial availability. Regional laboratories evaluate automated PCR, microbiology and immunoassay methods across respiratory, gastrointestinal and sexually transmitted infections. National health systems and hospital procurement bodies frequently negotiate testing prices, making workflow efficiency and reagent reliability important purchasing criteria. Decentralized testing is expanding selectively, but high-volume laboratory platforms remain central for complex diagnostic panels. Cross-country differences in reimbursement and implementation create a varied demand environment. European laboratories must consider IVDR compliance, local reimbursement and nationally organized procurement. Recent BD MAX assay certification illustrates how regulatory compliance affects availability. The choice of diagnostic workflow varies between large hospital networks and smaller community sites.
Priority country signals
Germany
Selected market signalGerman hospital and reference laboratories use regulated in vitro diagnostic products under European requirements. Platform integration and validated pathogen menus influence purchasing, particularly for high-throughput molecular testing and healthcare-associated infection workflows. German laboratory buyers assess IVDR conformity and the operational cost of molecular platforms. Hospital networks also consider automated specimen processing and the ability to add new pathogen targets without replacing instruments.
Source: BD.
United Kingdom
Selected market signalUK diagnostic services balance centralized laboratory testing with rapid assays where results can influence immediate clinical decisions. Tuberculosis, respiratory infections and antimicrobial stewardship are important considerations for assay selection. UK providers consider how diagnostic turnaround influences infection control and antimicrobial stewardship. Central laboratory networks can deliver broad testing menus, while selected urgent-care sites may benefit from smaller rapid systems.
Source: WHO.
Asia-Pacific
Access expansion - Diverse public-health needsAsia-Pacific combines highly developed diagnostic laboratories in Japan and other advanced healthcare markets with high-volume public-health testing needs in lower-resource settings. WHO tuberculosis diagnosis guidance is relevant to countries seeking improved detection of disease and drug resistance. Molecular technologies offer sensitivity and multiplex capabilities, but instrument cost, specimen logistics and trained staff can constrain deployment outside major urban centers. Point-of-care tests and smaller automated platforms can support decentralized access when they meet clinical performance requirements. Public procurement and local reimbursement influence market development, while infection patterns vary significantly across countries. Demand growth should be interpreted alongside differences in affordability and installed laboratory capacity. High-volume laboratories and decentralized public-health clinics face different cost and staffing requirements across Asia-Pacific. TB testing access is particularly relevant in some countries, while advanced hospital networks can deploy complex syndromic molecular assays. The region requires country-specific assumptions rather than one uniform uptake model.
Priority country signals
China
Selected market signalLarge urban hospitals and reference laboratories support automated molecular and immunoassay workflows. Procurement and local regulatory requirements influence the pace of new test adoption, while decentralized settings may require different instrument economics. Chinese diagnostic demand varies between large tertiary hospitals and lower-resource facilities. Procurement policies, local registration and supply continuity determine the economics of molecular panels and immunoassay testing.
Source: WHO.
India
Selected market signalIndia has a substantial need for accessible tuberculosis and respiratory infection diagnostics. WHO recommendations on automated nucleic acid amplification and drug-resistance detection provide a framework for evaluating appropriate technologies in public-health programs. Indian tuberculosis programs require reliable access to molecular testing, especially where drug resistance must be identified. Public procurement and decentralized specimen handling are essential to reaching patients beyond urban hospitals.
Source: WHO.
Latin America
Public procurement - Access and logistics matterLatin American demand is influenced by public procurement, urban laboratory infrastructure and the availability of affordable pathogen-specific testing. Hospitals and independent laboratories use molecular and conventional techniques according to local resources, while community programs need manageable sample transport and quality assurance. WHO guidance for tuberculosis diagnosis offers a framework for expanding access to rapid and accurate testing, particularly where drug-resistance information is clinically important. Regulatory pathways and reimbursement vary by country, affecting how quickly new assays enter routine care. Commercial opportunities therefore depend on cost per actionable result, reliable distribution and the ability to operate outside major metropolitan laboratories. Public-sector tenders and private laboratory chains shape testing purchases across Latin America. The practical ability to transport samples and maintain analyzers can matter as much as test sensitivity. Affordability and diagnostic turnaround remain key considerations for expanding services outside large cities.
Priority country signals
Brazil
Selected market signalBrazilian diagnostic laboratories serve both public and private healthcare systems, with demand for respiratory, gastrointestinal and tuberculosis testing. Decentralized programs must balance test sensitivity, supply availability and specimen transport constraints. Brazilian testing programs must balance public-health access with laboratory capacity and reagent supply. Regional differences in specimen transport can influence whether molecular tests are deployed locally or through centralized reference laboratories.
Source: WHO.
Mexico
Selected market signalMexican providers use a mix of molecular and immunoassay approaches, with procurement decisions influenced by laboratory throughput and care setting. Compact platforms may support rapid testing where centralized access is limited. Mexican laboratories compare test cost, turnaround and staff requirements when adding infectious disease assays. Community clinics may favor compact platforms, whereas large hospital systems can benefit from centralized automated workflows.
Source: CDC.
Middle East & Africa
Infrastructure-sensitive - TB diagnostics priorityMiddle East and Africa includes advanced hospital laboratory networks in some Gulf countries and resource-constrained public-health testing programs across other markets. Tuberculosis detection and drug-resistance testing remain significant priorities in relevant high-burden settings. WHO 2025 guidance supports the selection of molecular tests and appropriate diagnostic algorithms, but access depends on specimen collection, training, maintenance and financing. In higher-income healthcare systems, automated syndromic panels and rapid near-patient testing may support clinical workflow improvements. Elsewhere, procurement often prioritizes affordability, robustness and reliable consumable distribution. Differences in infrastructure and infection burden make region-wide demand projections particularly sensitive to local implementation. Testing infrastructure ranges from sophisticated Gulf hospital laboratories to rural public-health programs requiring resilient specimen logistics. WHO tuberculosis guidance addresses infection, disease and resistance testing in distinct clinical populations. Procurement models must reflect workforce capacity, reagent distribution and the feasibility of laboratory confirmation.
Priority country signals
South Africa
Selected market signalTuberculosis and drug-resistance diagnostics are important components of public-health testing. WHO recommendations emphasize appropriate molecular testing and reliable implementation, including quality assurance and diagnostic algorithms for vulnerable patients. South African tuberculosis diagnostic programs need tests that support actionable resistance information and dependable sample processing. Training, instrument maintenance and referral pathways are important implementation considerations.
Source: WHO.
United Arab Emirates
Selected market signalHospital and specialty laboratory procurement can support advanced automated molecular testing where instrument capacity and qualified personnel are available. Purchasing decisions weigh menu breadth, turnaround and the need for clinically actionable results. UAE hospitals can use sophisticated laboratory automation for respiratory and gastrointestinal infection testing. New platforms must demonstrate clinical value, compatibility with established workflows and predictable reagent availability.
Source: Roche.
Competitive Landscape
Competition spans automated molecular systems, point-of-care analyzers, immunoassay menus and syndromic panels. Product differentiation depends on validated pathogen targets, workflow, clinical sensitivity, installed platforms and the cost of routine testing. The manufacturers below have independently documented infectious disease assay offerings.
High-Throughput Molecular PlatformsRoche Diagnostics and Hologic
Roche offers cobas respiratory and STI testing assays across laboratory and near-patient instruments. Hologic has expanded its Panther Fusion gastrointestinal testing menu, including FDA-cleared bacterial and expanded bacterial assays announced in October 2025.
Syndromic PanelsbioM - rieux and Cepheid
bioM - rieux markets BIOFIRE FILMARRAY TORCH with respiratory, gastrointestinal and bloodstream infection panels. Cepheid offers GeneXpert molecular testing and an Xpert Respiratory Panel covering 13 pathogen targets.
Rapid Near-Patient TestingAbbott Laboratories
Abbott ID NOW uses isothermal nucleic acid amplification for rapid detection of infectious pathogens. The compact format addresses settings where a timely result can inform clinical decisions without a conventional central laboratory workflow.
Automated Laboratory PCRBD and Certest Biotec
BD MAX integrates nucleic acid extraction and PCR detection. BD announced an expansion of its European assay menu in December 2025 using IVDR-certified VIASURE assays developed with Certest Biotec.
Competitive advantage is closely linked to the installed instrument base and the ability to add clinically relevant assays without disruptive changes to laboratory workflows. Manufacturers seek to reduce operator time, simplify sample preparation and maintain dependable consumable supplies. Regulatory clearance and clinical validation remain prerequisites for adoption in each intended setting. Buyers also evaluate turnaround time, specimen compatibility and whether multiplex testing improves decisions sufficiently to justify its cost. Across clinical segments, procurement is rarely determined by the number of detectable pathogens alone. Sample throughput, diagnostic stewardship, technical support, service contracts and laboratory information system integration can materially influence purchasing. Manufacturers therefore compete on the entire workflow rather than an isolated assay result.
Partnerships between analyzer manufacturers and assay developers can extend menus while reducing the need to design a new instrument. The BD and Certest Biotec relationship illustrates this approach. Laboratories should distinguish manufacturer claims about target coverage from independently validated clinical performance and assess each assay according to its authorization, intended use and local care pathway.
Key Companies Profiled
- Abbott Laboratories
- Roche Diagnostics
- bioM - rieux SA
- Becton, Dickinson and Company
- Cepheid (Danaher)
- Hologic Inc.
- Certest Biotec
Recent Developments in the Infectious Disease Diagnostics Testing Market
December 2025: BD announced IVDR certification of VIASURE respiratory and STI assays for the BD MAX system in Europe. The expanded menu supports detection of multiple respiratory pathogens and sexually transmitted infections through an automated molecular workflow. The announcement demonstrates continued assay portfolio expansion through a development partnership. Source
October 2025: Hologic announced U.S. FDA clearance and European IVDR CE marking for Panther Fusion gastrointestinal bacterial and expanded bacterial assays. The products identify multiple enteric pathogens using an automated molecular testing system and are designed to help clinical laboratories obtain targeted diagnostic results. The clearance allows Hologic to offer the named gastrointestinal bacterial assays in the relevant authorized markets. Source
August 2025: Roche announced FDA clearance for cobas Respiratory 4-flex, a molecular test differentiating SARS-CoV-2, influenza A, influenza B and RSV. The assay runs on cobas 5800, 6800 and 8800 systems and uses Roche TAGS technology, extending respiratory testing capabilities for laboratories with compatible instruments. The respiratory assay clearance expands the options available for multiplex testing on compatible cobas laboratory systems. Source
August 2025: WHO published an updated operational handbook on tuberculosis diagnosis. The document integrates guidance on infection, active disease and drug resistance, discusses automated nucleic acid amplification and sequencing, and provides diagnostic algorithms for different patient populations. It supports implementation planning for national TB programs. The WHO handbook informs selection of tuberculosis tests and diagnostic algorithms for public-health implementation. Source
January 2025: Roche announced FDA clearance and a CLIA waiver for cobas liat sexually transmitted infection assays covering CT/NG and CT/NG/MG targets. The company describes PCR-based results in 20 minutes, supporting testing in decentralized professional care settings where same-visit decisions can improve patient management. The clearance expands the options for rapid STI molecular testing at professional care sites. Source
September 2025: CDC updated its information on the Influenza SARS-CoV-2 multiplex assay, which can simultaneously detect and distinguish influenza A, influenza B and SARS-CoV-2. The agency describes its role in conserving testing materials and supporting surveillance when respiratory viruses co-circulate. Its multiplex design is relevant to respiratory pathogen differentiation in clinical laboratories. Source
Market Outlook, 2027–2036
The infectious disease diagnostics testing market is estimated to grow from USD 17.8 billion in 2027 to USD 23.7 billion by 2036, equivalent to a 3.2% CAGR during 2027–2036. Growth reflects broader clinical use of molecular diagnostics and incremental access to rapid testing, balanced against procurement and reimbursement constraints.
| Forecast Variable | 2027 Baseline | Expected Effect Through 2036 |
|---|
| Molecular assay menus | Multiplex respiratory and STI platforms | More clinically relevant targets and workflow consolidation |
| Near-patient testing | Rapid molecular and antigen formats | Selective expansion in community and urgent-care settings |
| TB diagnostics | WHO 2025 consolidated diagnosis guidance | Demand for accurate testing and resistance detection |
| Laboratory automation | Established cobas, BD MAX and Panther platforms | Instrument-menu expansion and reagent utilization |
| Pricing and procurement | Budget and reimbursement constraints | Moderation of revenue growth per test |
| Regulatory compliance | FDA clearances and European IVDR | Ongoing validation and implementation requirements |
Clinical demand is expected to favor assays that produce actionable results within a useful treatment window. Respiratory syndromic panels, molecular STI tests and tuberculosis diagnostics provide distinct opportunities. Laboratories will continue to balance speed and sensitivity with specimen logistics, quality assurance and the total cost of testing. Broad molecular menus should expand selectively where clinical evidence supports their use.
Growth in decentralized testing depends on whether clinics can reliably operate compact platforms and whether payers reimburse the resulting tests. Rapid molecular systems can reduce delays for selected conditions, but centralized laboratories retain advantages in high-throughput processing and complex workups. The most successful suppliers are likely to offer complementary formats rather than relying on a single testing environment.
The principal risks are reimbursement pressure, expensive equipment, regulatory delays and uneven diagnostic access. Manufacturers also face the need to maintain reliable reagent supply, instrument service and operator training. Molecular test performance must be interpreted in clinical context, and expanded pathogen panels do not automatically produce better outcomes unless their results guide treatment or infection-control decisions.
North America is expected to retain a large share of revenue, while Asia-Pacific, Latin America and parts of Africa have opportunities to improve diagnostic access through public-health programs and decentralized testing. Regional forecasts remain sensitive to procurement funding and the pace of laboratory infrastructure development. The published market values are normalized from publisher revenue endpoints and are not presented as directly measured global sales.
Report Coverage
The study covers commercial infectious disease diagnostic products and testing platforms across technology, clinical indication, care setting and geographic demand.
Market Size and Forecast2026 base-year revenue, 2027 estimate, 2036 forecast and CAGR for 2027–2036.
Technology SegmentationMolecular diagnostics, antigen and immunoassays, culture and other methods.
Clinical ApplicationsRespiratory, STI, TB, gastrointestinal, bloodborne and other infectious diseases.
End Users and SettingsHospitals, reference laboratories, clinics, point-of-care and home-testing formats.
Regional AnalysisNorth America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Competitive and Regulatory ReviewAssay portfolios, FDA clearances, IVDR compliance and recent product developments.
Frequently Asked Questions
How large is the infectious disease diagnostics testing market?
The market is modeled at USD 17.2 billion in 2026 and estimated at USD 17.8 billion in 2027, with a forecast of USD 23.7 billion by 2036. The estimates are normalized from the supplied 2024 and 2032 publisher revenue values. The forecast uses 2024 and 2032 publisher revenue observations and is extended to the required 2026, 2027 and 2036 framework using a consistent annual growth rate.
What is the forecast CAGR for 2027–2036?
The modeled CAGR is 3.2% for 2027–2036, calculated using the supplied publisher revenue endpoints. The publisher separately stated 3.8% for an earlier forecast period. This CAGR describes projected market revenue rather than diagnostic test volume, which may change at a different rate as prices and assay mix evolve.
Which technology leads the market?
Molecular diagnostics represented an estimated ~44% of 2026 revenue, reflecting widespread PCR and other nucleic acid amplification testing in laboratories and near-patient settings. The category includes both high-throughput laboratory PCR and rapid near-patient nucleic acid amplification platforms, with instrument and consumable costs affecting adoption.
Which application is largest?
Respiratory infection testing represented an estimated ~31% of 2026 revenue, including testing for influenza, SARS-CoV-2, RSV and other respiratory pathogens. The respiratory category spans multiple pathogens with overlapping symptoms, making timely differentiation valuable when it changes antiviral treatment or infection-control decisions.
Which region has the largest market share?
North America represented an estimated ~38% of global 2026 revenue, supported by established laboratory networks and access to automated molecular and point-of-care platforms. The 2026 revenue allocation reflects the presence of established clinical laboratory networks, regulatory pathways and commercial adoption of pathogen-specific molecular assays.
What is multiplex infectious disease testing?
Multiplex testing detects or differentiates multiple pathogen targets using one assay workflow. Examples include Roche cobas Respiratory 4-flex and Cepheid Xpert Respiratory Panel. Such panels can streamline sequential testing, although laboratories must assess whether the additional targets are clinically appropriate for the patient population.
How do molecular and antigen tests differ?
Molecular assays detect pathogen genetic material, while antigen tests detect pathogen proteins. CDC guidance notes that antigen tests can be less sensitive, although they may deliver results rapidly. Negative antigen findings may require molecular follow-up when clinical suspicion remains high, and testing decisions should follow the intended use and clinical context.
Why is point-of-care testing growing?
Rapid molecular testing can support clinical decisions during a single patient visit. Roche cobas liat STI assays and Abbott ID NOW illustrate platforms designed for near-patient professional use. Adoption depends on operator training, quality controls, reimbursement and whether a timely result improves clinical management before the patient leaves the care site.
How does tuberculosis influence diagnostics demand?
WHO 2025 guidance emphasizes molecular testing and appropriate algorithms for detecting tuberculosis disease, infection and drug resistance, supporting continued public-health investment in diagnostic access. Programs must also address specimen transport, staff training, equipment maintenance and access to confirmatory tests to implement WHO recommendations effectively.
Who are leading manufacturers?
Documented suppliers include Abbott, Roche Diagnostics, bioM - rieux, BD, Cepheid, Hologic and Certest Biotec. The cited portfolios include ID NOW, cobas, BIOFIRE, BD MAX, GeneXpert and Panther Fusion. Manufacturer offerings vary in throughput, specimen type, authorized indication and assay menu; the list reflects independently evidenced product activity rather than a market-share ranking.
What restrains market growth?
Budget constraints, reimbursement, regulatory validation, laboratory staffing and reagent supply can limit the pace of adoption even when faster or more sensitive tests are available. These operational constraints can affect the number of tests performed and the price that health systems are willing to pay for new technologies.
What years and regions does this report cover?
The report uses a 2026 base year, 2027 estimate and 2036 forecast, covering North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Regional analysis includes selected countries and four independent segmentation dimensions, with forecast growth expressed for the nine years from 2027 through 2036.
Research Sources & Evidence Base
View research sources used for this overview
- WHO. Tuberculosis diagnosis handbook update, 2025-08-11.
- WHO. Consolidated TB diagnosis guidelines, 2025.
- CDC. Influenza SARS-CoV-2 multiplex assay, 2025-09-02.
- CDC. Respiratory virus testing guidance, 2025-08-18.
- CDC. Rapid molecular influenza diagnostic assays, 2026.
- Roche Diagnostics. cobas Respiratory 4-flex FDA clearance, 2025-08-04.
- Roche. cobas liat STI point-of-care molecular assays, 2025-01-22.
- Roche Diagnostics. Dried blood spot testing access, 2025-10-09.
- Abbott. ID NOW rapid molecular platform, undated.
- bioMerieux. BIOFIRE FILMARRAY TORCH multiplex panels, undated.
- BD. BD MAX molecular diagnostics system, undated.
- BD. IVDR VIASURE assays for BD MAX, 2025-12-15.
- Cepheid. Xpert respiratory panel, undated.
- Hologic. FDA clearance for Panther Fusion GI assays, 2025-10-02.
- CDC. Multiplex influenza SARS-CoV-2 RSV testing, 2026-04-27.